Posted by Michael Wonder on 12 Nov 2018
Billion dollar drug company wants to be 'reimbursed' with taxpayer funding
11 November 2018 - An American drug company which hopes to treat New Zealand children for a rare genetic disorder has been accused of unethical pricing overseas.
An American drug company demanding $1 million taxpayer funding to treat New Zealand children with a rare genetic disorder has already been rebuffed by overseas authorities who accused the company of unethical pricing.
Biogen has been supporting the Muscular Dystrophy Association of New Zealand and is offering free medication to children with spinal muscular atrophy as it attempts to win support to get its drug Spinraza publicly-funded.
